Health Catalyst (NASDAQ:HCAT) Price Target Raised to $10.50 at Citigroup

Health Catalyst (NASDAQ:HCAT) had its price objective hoisted by Citigroup from $9.00 to $10.50 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price target would suggest a potential upside of 18.78% from the company’s previous close.

A number of other equities research analysts have also weighed in on HCAT. Royal Bank of Canada boosted their target price on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Stephens lowered their target price on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Evercore ISI increased their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Finally, Piper Sandler dropped their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.54.

Health Catalyst Stock Up 8.7 %

HCAT stock traded up $0.71 during trading hours on Wednesday, reaching $8.84. 191,829 shares of the stock were exchanged, compared to its average volume of 561,621. The company has a market cap of $537.91 million, a price-to-earnings ratio of -6.55 and a beta of 1.32. Health Catalyst has a 12 month low of $5.42 and a 12 month high of $11.41. The firm’s 50-day moving average is $8.11 and its 200-day moving average is $7.19. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. During the same period in the previous year, the firm posted ($0.22) EPS. The firm’s revenue was up 3.5% compared to the same quarter last year. On average, equities research analysts expect that Health Catalyst will post -0.35 earnings per share for the current year.

Insiders Place Their Bets

In related news, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the transaction, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now owns 140,108 shares of the company’s stock, valued at approximately $1,062,018.64. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,396 shares of company stock worth $266,280. 2.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HCAT. First Light Asset Management LLC lifted its position in shares of Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after buying an additional 3,221,408 shares during the last quarter. Millennium Management LLC raised its stake in Health Catalyst by 96.3% during the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after buying an additional 1,184,131 shares during the last quarter. Kennedy Capital Management LLC bought a new stake in Health Catalyst in the first quarter worth approximately $8,780,000. Nepsis Inc. boosted its holdings in Health Catalyst by 67.9% in the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after acquiring an additional 851,448 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its holdings in Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after purchasing an additional 360,201 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.